Vimarsana
Biggest News Aggregation in the World

Davidp Carbone News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Davidp Carbone. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Davidp Carbone Today - Breaking & Trending Today

'We were shocked': Vaping considerably increases lung cancer risk among people who smoke - Vimarsana News

'We were shocked': Vaping considerably increases lung cancer risk among people who smoke

People who vaped and smoked cigarettes appeared four times more likely to develop lung cancer compared with those who only smoked, according to study results presented at American Association for Cancer Research Annual Meeting. Marisa A. Bittoni, PhD, MS, research assistant professor at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard

Source: healio.com
Imdelltra Gets Accelerated Approval for Extensive-Stage SCLC - Vimarsana News

Imdelltra Gets Accelerated Approval for Extensive-Stage SCLC

The FDA has granted accelerated approval to Imdelltra (tarlatamab-dlle) for extensive stage small cell lung cancer.

Source: empr.com
Tarlatamab Receives Accelerated Approval for Extensive-Stage SCLC - Vimarsana News

Tarlatamab Receives Accelerated Approval for Extensive-Stage SCLC

The FDA has approved tarlatamab, a novel bispecific T-cell engager, to treat patients with extensive-cell small cell lung cancer (SCLC).

Source: ajmc.com
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER - Vimarsana News

FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor

Source: kpvi.com
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER - Vimarsana News

FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the...